[go: up one dir, main page]

ES2138561B1 - Uso de los peptidos vip y pacap en el tratamiento del shock endotoxico en mamiferos. - Google Patents

Uso de los peptidos vip y pacap en el tratamiento del shock endotoxico en mamiferos.

Info

Publication number
ES2138561B1
ES2138561B1 ES009800814A ES9800814A ES2138561B1 ES 2138561 B1 ES2138561 B1 ES 2138561B1 ES 009800814 A ES009800814 A ES 009800814A ES 9800814 A ES9800814 A ES 9800814A ES 2138561 B1 ES2138561 B1 ES 2138561B1
Authority
ES
Spain
Prior art keywords
pacap
mammals
treatment
endotoxic shock
vip
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES009800814A
Other languages
English (en)
Other versions
ES2138561A1 (es
Inventor
Gomariz Rosa Perez
Martinez Javier Leceta
Mora Mario Delgado
Mora Carmen Martinez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidad Complutense de Madrid
Original Assignee
Universidad Complutense de Madrid
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES009800814A priority Critical patent/ES2138561B1/es
Application filed by Universidad Complutense de Madrid filed Critical Universidad Complutense de Madrid
Priority to PCT/ES1999/000101 priority patent/WO1999053944A1/es
Priority to AT99913324T priority patent/ATE228006T1/de
Priority to DE69904010T priority patent/DE69904010T2/de
Priority to PT99913324T priority patent/PT1002542E/pt
Priority to EP99913324A priority patent/EP1002542B1/en
Priority to US09/446,352 priority patent/US6429188B1/en
Priority to JP55251999A priority patent/JP2002507224A/ja
Priority to AU31486/99A priority patent/AU3148699A/en
Priority to CA002294980A priority patent/CA2294980A1/en
Priority to ES9901235A priority patent/ES2160495B1/es
Publication of ES2138561A1 publication Critical patent/ES2138561A1/es
Application granted granted Critical
Publication of ES2138561B1 publication Critical patent/ES2138561B1/es
Priority to US10/090,109 priority patent/US20020151458A1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Manufacture Of Tobacco Products (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)

Abstract

Uso de los péptidos VIP (Péptido intestinal vasoactivo) y PACAP ( Péptido inhibidor de la adenilato ciclasa hipofisiaria) en la preparación de fármacos para el tratamiento del shock endotóxico en mamíferos. Estos preparados inhiben la producción del factor de necrosis tumoral e interleuquina 6.
ES009800814A 1998-04-17 1998-04-17 Uso de los peptidos vip y pacap en el tratamiento del shock endotoxico en mamiferos. Expired - Fee Related ES2138561B1 (es)

Priority Applications (12)

Application Number Priority Date Filing Date Title
ES009800814A ES2138561B1 (es) 1998-04-17 1998-04-17 Uso de los peptidos vip y pacap en el tratamiento del shock endotoxico en mamiferos.
AU31486/99A AU3148699A (en) 1998-04-17 1999-04-16 Method for treating the endotoxic shock in mammals
DE69904010T DE69904010T2 (de) 1998-04-17 1999-04-16 Verwendung von vip zur erstellung eines medikamentes zur behandlung des endotoxischen schocks in säugetieren
PT99913324T PT1002542E (pt) 1998-04-17 1999-04-16 Utilizacao de vip para a preparacao de um medicamento destinado ao tratamento de choque endotoxico em mamiferos
EP99913324A EP1002542B1 (en) 1998-04-17 1999-04-16 Use of vip for the preparation of a medicament for treating the endotoxic shock in mammals
US09/446,352 US6429188B1 (en) 1998-04-17 1999-04-16 Method for treating the endotoxic shock in mammals
PCT/ES1999/000101 WO1999053944A1 (es) 1998-04-17 1999-04-16 Metodo para el tratamiento del 'shock' endotoxico en mamiferos
AT99913324T ATE228006T1 (de) 1998-04-17 1999-04-16 Verwendung von vip zur erstellung eines medikamentes zur behandlung des endotoxischen schocks in säugetieren
CA002294980A CA2294980A1 (en) 1998-04-17 1999-04-16 Method for the treatment of endotoxic shock in mammels
JP55251999A JP2002507224A (ja) 1998-04-17 1999-04-16 哺乳類におけるエンドトキシンショックの治療方法
ES9901235A ES2160495B1 (es) 1998-04-17 1999-06-04 Uso de los peptidos vip y pacap para el tratamiento de enfermedades inflamatorias y autoinmunes en mamiferos.
US10/090,109 US20020151458A1 (en) 1998-04-17 2002-03-04 Method for treating and preventing septic shock with VPAC1R, VPAC2R and PAC1R agonists

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES009800814A ES2138561B1 (es) 1998-04-17 1998-04-17 Uso de los peptidos vip y pacap en el tratamiento del shock endotoxico en mamiferos.

Publications (2)

Publication Number Publication Date
ES2138561A1 ES2138561A1 (es) 2000-01-01
ES2138561B1 true ES2138561B1 (es) 2000-07-01

Family

ID=8303495

Family Applications (1)

Application Number Title Priority Date Filing Date
ES009800814A Expired - Fee Related ES2138561B1 (es) 1998-04-17 1998-04-17 Uso de los peptidos vip y pacap en el tratamiento del shock endotoxico en mamiferos.

Country Status (10)

Country Link
US (1) US6429188B1 (es)
EP (1) EP1002542B1 (es)
JP (1) JP2002507224A (es)
AT (1) ATE228006T1 (es)
AU (1) AU3148699A (es)
CA (1) CA2294980A1 (es)
DE (1) DE69904010T2 (es)
ES (1) ES2138561B1 (es)
PT (1) PT1002542E (es)
WO (1) WO1999053944A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1103270E (pt) * 1999-06-04 2003-08-29 Univ Madrid Complutense Tratamento de doencas auto-imunes em mamiferos
AU2003239819A1 (en) * 2002-05-08 2003-11-11 Bayer Aktiengesellschaft Diagnostics and therapeutics for diseases associated with vasoactive intestinal peptide receptor 2 (vpac2)
US7547450B2 (en) * 2002-10-24 2009-06-16 Nestec Ltd. Senior feline food
WO2004073733A1 (ja) * 2003-02-24 2004-09-02 Morinaga Milk Industry Co., Ltd. インターロイキン−６産生抑制剤
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US8334257B2 (en) 2005-12-20 2012-12-18 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
EP4074327A1 (en) 2008-06-27 2022-10-19 Duke University Therapeutic agents comprising elastin-like peptides
RU2589255C2 (ru) * 2009-08-14 2016-07-10 Фейзбайо Фармасьютикалз, Инк. Модифицированные вазоактивные интестинальные пептиды
US9561262B2 (en) 2011-06-06 2017-02-07 Phasebio Pharmaceuticals, Inc. Use of modified vasoactive intestinal peptides in the treatment of hypertension
AU2015255752B2 (en) 2014-05-08 2020-07-23 Immunoforge Co., Ltd. Methods and compositions for treating Cystic Fibrosis
EP3256151B1 (en) 2015-02-09 2020-08-05 Phasebio Pharmaceuticals, Inc. Methods and compositions for treating muscle disease and disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6429221B1 (en) * 1994-12-30 2002-08-06 Celgene Corporation Substituted imides

Also Published As

Publication number Publication date
WO1999053944A1 (es) 1999-10-28
ATE228006T1 (de) 2002-12-15
US6429188B1 (en) 2002-08-06
DE69904010D1 (de) 2003-01-02
AU3148699A (en) 1999-11-08
EP1002542A1 (en) 2000-05-24
PT1002542E (pt) 2003-04-30
EP1002542B1 (en) 2002-11-20
JP2002507224A (ja) 2002-03-05
CA2294980A1 (en) 1999-10-28
ES2138561A1 (es) 2000-01-01
DE69904010T2 (de) 2003-08-21

Similar Documents

Publication Publication Date Title
ES2138561B1 (es) Uso de los peptidos vip y pacap en el tratamiento del shock endotoxico en mamiferos.
DE69731373D1 (de) Cc-chemokinzeptor c-c ckr-5, dessen derivate und verwendungen
DK0960127T3 (da) Isoleret dimert fibroblastaktiverende protein-alfa og anvendelser deraf
DE69930327D1 (de) Oxazolo-, Thiazolo- und Selenazolo-Ä4,5-cÜnaphthyridin-4-amine und Analoge davon
MX9205240A (es) Composicion y metodo para tratar hepatitis c.
PT907652E (pt) Compostos e processos imunossupressores
DE59200089D1 (de) Hochdruckentladungslampe kleiner Leistung.
DK1294757T3 (da) Glucagonlignende peptid 1-analoger
DE69737787D1 (de) Zyklische somatostatin-analoge mit einer hauptkette mit einer gespannten konformation
AR016981A2 (es) Polipeptidos sinteticos
DK0593585T3 (da) Peptid, som modvirker TNF- og LPS-toksicitet
ES2058191T3 (es) Acidos 2-fenil-4-quinolincarboxilicos substituidos.
NO982727D0 (no) PGE-holdige lyofiliserte liposomer for anvendelse i behandling av erektil dysfunksjon
ITMI932412A0 (it) Uso di alfa 1-bloccanti nel trattamento della eiaculazione precoce
TR199901190T2 (xx) Interferon-(alfa) N�kleik asitlerinin verilmesi ve sentezlenmesi i�in y�ntemler ve bile�imler.
ES2166900T3 (es) Derivados de ara-c.
ATE118016T1 (de) Peptid mit einer aktivität gegen metastasen.
ZA929390B (en) The use of D-fenfluramine and fenfluramine compounds in the treatment of hypertension in insulin-resistant subjects.
EP0647138A4 (en) POLYPEPTIDES AVAILABLE FROM FASCIOLA SPECIES, AND VACCINE, THERAPY PROCEDURES AND DNA SEQUENCES ENCODING THESE PEPTIDES.
MX9102512A (es) Administracion oral de interferon alfa en el tratamiento de enfermedades del pulmon.
ITRM910710A1 (it) Metodo per la determinazione del fattore di necrosi tumorale (tnf) in forma biologicamente attiva.
ES2066897T3 (es) 5,11-dihidro-6h-pirido(2,3-b)(1,4)benzodiazepin-6-onas y -tionas y su uso en la prevencion o el tratamiento del sida.
DE3777359D1 (de) Aminosaeuresequenz des menschlichen alpha 2-plasmininhibitors und cdns sowie diese aminosaeuresequenz codierende genomische dns.
DE60002143D1 (de) Behandlung autoimmunerkrankungen in säugern
ES2167942T3 (es) Empleo de 2-aminotetralinas 6,7-sustituidas apropiadas para la preparacion de una composicion farmaceutica para el tratamiento terapeutico de patologias inflamatorias y/o autoinmunes.

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20000101

Kind code of ref document: A1

Effective date: 20000101

FD2A Announcement of lapse in spain

Effective date: 20180726